ArticlePediatric cardiology2017
Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
Article in Pediatric cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Circulating Growth Differentiation Factor 15 (GDF15) in Paediatric Disease: A Systematic Review.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Accuracy of brain natriuretic peptide and N-terminal brain natriuretic peptide for detecting paediatric pulmonary hypertension: a systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Circulating levels of growth differentiation factor-15 and its genetic variants -3148C>G (rs4808793) in pediatric cardiac patients.World journal of clinical pediatrics · 2026Article
- Group D of pulmonary arterial hypertension and its relationship to congenital heart disease: Is there a non-invasive way to predict the unpredictable?Global cardiology science & practice · 2025Review
- Correlation of Serum Growth Differentiation Factor 15 With Metabolic Syndrome and Its Components in Patients With Type 2 Diabetes Mellitus.Journal of diabetes research · 2025Article
- GDF15 as a key disease target and biomarker: linking chronic lung diseases and ageing.Molecular and cellular biochemistry · 2024Review
- Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics.BMC cardiovascular disorders · 2023Article
- Pulmonary arterial hypertension associated with congenital heart disease: An omics study.Frontiers in cardiovascular medicine · 2023Review
- Correlation between serum GDF-15 level and pulmonary vascular morphological changes and prognosis in patients with pulmonary arterial hypertension.Frontiers in cardiovascular medicine · 2023Article
- Growth and differentiation factor 15 (GDF15) levels predict adverse respiratory outcomes in premature neonates.Pediatric pulmonology · 2023Article
- Heart Failure Risk Predictions and Prognostic Factors in Adults With Congenital Heart Diseases.Frontiers in cardiovascular medicine · 2022Review
- Prognostic biomarkers in pediatric pulmonary arterial hypertension.Cardiovascular diagnosis and therapy · 2021Review
- Growth differentiation factor 15 neutralization does not impact anorexia or survival in lipopolysaccharide-induced inflammation.iScience · 2021Article
- A new diagnostic indication device of a biomarker growth differentiation factor 15 for mitochondrial diseases: From laboratory to automated inspection.Journal of inherited metabolic disease · 2021Article
- Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension.The Journal of pediatrics · 2020Article
- Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal growth and adiposity measurements.Pediatric research · 2020Article
- Role of Growth Differentiation Factor 15 in Lung Disease and Senescence: Potential Role Across the Lifespan.Frontiers in medicine · 2020Review
- Serum GDF15, a Promising Biomarker in Obese Patients Undergoing Heart Surgery.Frontiers in cardiovascular medicine · 2020Article
- Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.Chinese medical journal · 2019Article
- GDF-15 in Pulmonary and Critical Care Medicine.American journal of respiratory cell and molecular biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
We aimed to investigate plasma growth differentiation factor-15 (GDF-15) levels in pediatric pulmonary arterial hypertension secondary to congenital heart disease (PAH-CHD), and assess the association with hemodynamic parameters. Plasma GDF-15 levels were measured in children with PAH-CHD (n = 46) and compared to children with CHD without PAH (n = 39). Normal individuals (n = 30) served as health control group. Plasma GDF-15 levels were significantly elevated in patients with PAH-CHD compared with those with CHD without PAH (median 1415 ng/L, interquartile range [IQR] 926.7-2111.7 ng/L vs. 890.6 ng/L, IQR 394.7-1094.3 ng/L, p < 0.01). Elevated plasma GDF-15 levels were positively related to Functional Class, uric acid, N-terminal pro-B-type natriuretic peptide (NT-proBNP), pulmonary artery systolic pressure, mean pulmonary artery pressure, pulmonary blood flow/systemic blood flow and pulmonary vascular resistance, and a lower mixed venous oxygen saturation (Sv
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.